Catching up on clinical trials
Learn more about existing studies and their future impacts.

The Learning Lab will be a top destination on Sunday with its slate of sessions featuring Clinical Trials in Progress. The program, which is new at AUA2024, offers members the opportunity to learn about cutting-edge studies that are testing therapies and technologies for common urological diseases.
AUA Secretary David F. Penson, MD, MPH
“This is an opportunity to learn what’s coming down the pike and learn what drugs and devices we’ll be using in five or 10 years,” said Dr. Penson, who is also the Hamilton and Howd Chair in urologic oncology, and professor and chair of the department of urology at Vanderbilt University Medical Center in Nashville.
These are clinical trials that are in progress, so results won’t be available yet, but attendees can understand the stage of each study and how its outcomes will be relevant to urologists. The audience will also be able to interact with the studies’ investigators and sponsors to ask questions and provide feedback.
“Often, the first time urologists hear about new agents or devices is after (or sometimes long after) [Food and Drug Administration] approval, which slows down the diffusion of new and more effective treatments,” Dr. Penson said. “By presenting ongoing work at the Annual Meeting, those in attendance can get a leg up and can prepare to add these new agents and devices to their armamentarium as soon as they are approved and available for use.”